Abstract
Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells. We further confirm the bone metastasis-promoting function of osteoblast-derived Jagged1 using osteoblast-specific Jagged1 transgenic mouse model. These findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bone metastasis. Zheng et al. develop 15D11, a fully human monoclonal antibody to Jagged1, which inhibits Jagged1 on breast cancer cells as well as blocking metastasis-promoting effects of osteoblast-derived Jagged1 induced by chemotherapy. 15D11 reduces bone metastasis and sensitizes metastases to chemotherapy in mouse models of breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 731-747.e6 |
Journal | Cancer Cell |
Volume | 32 |
Issue number | 6 |
DOIs | |
State | Published - Dec 11 2017 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Keywords
- Jagged1
- bone metastasis
- breast cancer
- chemoresistance
- neutralizing antibody
- osteoblastic niche
- osteoblasts